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Background
In the Phase III, randomised, open-label ODIN trial,
treatment-experienced HIV-1-infected adults with no
screening DRV resistance-associated mutations received
DRV/r 800/100mg qd or DRV/r 600/100mg bid (both
arms + ≥2 NRTIs). At Week 48, 72.1% qd vs 70.9% bid
patients achieved HIV-1 RNA <50 copies/mL (95% CI =
-6.1 to 8.5%, p<0.001; ITT-TLOVR), confirming non-
inferiority of DRV/r qd. The relationship between DRV
PK and efficacy and safety following treatment with
DRV/r is explored.
Methods
Sparse blood sampling for PK evaluations was taken at
Weeks 4, 8, 24 and 48 to determine DRV trough con-
centrations (C0h) and exposure (AUC24h, calculated as
AUC12h x 2 for bid) using a population pharmacokinetic
model. Relationships between PK parameters and effi-
cacy (change in log10 HIV-1 RNA and virological
response [HIV-1 RNA <50 copies/mL]) were assessed
using ANCOVAs. Relationships between PK parameters
and occurrence of adverse events of interest and labora-
tory lipid abnormalities were evaluated using descriptive
statistics.
Results
PK data were available for 280 DRV/r qd patients and
278 bid patients. Median (range) C0h was 1896 (184-
7881) ng/mL for DRV/r qd and 3197 (250-11,865) ng/mL
for DRV/r bid. Median (range) AUC24h for DRV/r qd was
87,788 (45,456-236,920) ng.h/mL and 109,401 (48,934–
323,820) ng.h/mL for bid. No relevant relationships were
observed between DRV PK and efficacy: changes from
baseline in HIV-1 RNA log10 copies/mL at Week 48 for
pooled data by DRV AUC24h quartile ranges (≤79,576;
79,577-100,376; 100,377-119,356; >119,356 ng.h/mL)
were -2.06, -2.22, -2.19, and -2.08 log10 copies/mL,
respectively. The % patients achieving HIV-1 RNA <50
copies/mL by these quartile ranges were 82.0%, 88.5%,
82.6% and 76.5% (observed data), respectively. In a logis-
tic regression analysis adjusting for baseline viral load,
AAG levels and number of sensitive NRTIs in the opti-
mised background regimen, there were no relevant rela-
tionships between PK and virological response. No
apparent relationships were observed between DRV PK
and occurrence of rash-, cardiac-, GI-, liver-, lipid- and
glucose-related AEs or laboratory lipid abnormalities.
Conclusions
Dosing with DRV/r 800/100mg qd resulted in lower C0h
and AUC24h compared to DRV/r 600/100mg bid; how-
ever, comparable efficacy between DRV/r qd and bid
confirmed adequate DRV concentrations were achieved
following qd dosing. No relevant relationships were
observed between DRV PK and efficacy or safety at
Week 48.
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